If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
129.00    1.00 (0.78%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £537.17m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Trading Update

29 Jul 2025 07:00

RNS Number : 8873S
James Halstead PLC
29 July 2025
 

 

29 July 2025

 

 

JAMES HALSTEAD PLC (the "Company")

 

Trading Update

James Halstead plc, the commercial flooring manufacturer and international distributor, is providing the following trading update ahead of its results for the year ended 30 June 2025.

 

The Company sells, for the most part, commercial flooring across the world and has seen continued confidence in the segment of resilient sheet flooring but has experienced headwinds against sales of luxury vinyl tile (LVT) principally in Europe, the Company has however successfully managed to grow its market share in the UK. Profit before tax is in line with expectations.

 

Sales in the UK, our largest market, have improved compared to the prior financial year. Having reported that in the prior financial year there was a 5% decline versus the comparative, it is pleasing to note that our performance this year has seen this decline more than fully reverse. This is despite a degree of de-stocking by some customers, particularly those with exposure to the UK domestic carpet market.

 

Sales volumes of LVT have increased, albeit modestly, in a market segment that has seen a large decline in demand. Sales of Polyflor branded LVT products have held up due to their quality and value together with our widely accepted reputation for sustainability and environmental excellence; factors that have helped increase our market share. LVT and sheet vinyl continue to displace carpet sales in the UK market.

 

Notwithstanding this backdrop and solid UK performance, our internal expectations for the UK were higher. An anticipated uplift in demand in the education, healthcare and the prison sectors has not, yet, materialised though sales into the aged care and affordable housing sectors are performing satisfactorily.

 

In Europe, particularly in France and Holland, there has been muted activity in consumer spending which has affected refurbishment demand and new store openings in the retail sector. This has impacted LVT sales and volume declines were further compounded by increased focus of government budgets towards national security, diverting spending away from such areas as construction and social housing.

 

The products we sell are still regarded as market leading but the year has required reacting to a lower level of sales by tight cost control. In this regard, the simple model of holding stock within our distribution chain to supply demand is tried and tested around the globe.

 

In our Rest of World markets, sales have generally been more positive with very good growth, especially in the Americas, the Middle East and Mediterranean regions. Additionally, South Asia has seen the growth of recent years continue and is 38% ahead of the comparative of last year.

 

Notwithstanding the slower sales, the Group's focus on manufacturing efficiency and tight cost control of overheads have protected margins.

 

Operationally, there has been disruption to global trade routes and shipping movements with the uncertainty of tariffs on sales into the USA which has affected deliveries into many markets. However, these uncertainties have been positive regarding the sale of our UK manufactured goods into the USA, as customers seek alternative suppliers to replace products imported from countries where much higher tariffs have been imposed and with continuing uncertainly. This increased demand is despite an additional 10% duty cost to importers of our UK products.

 

In summary, the Company anticipates that sales will be marginally below the 2024 comparative with profit slightly below last year's record levels; although remaining within the range of market expectations. Cash generation alongside reserves continue to underpin an ungeared balance sheet, which remains strong.

 

The Board is confident that the prospects remain solid despite the recent external challenges and side winds.

 

The Company expects to announce its results for the year ended 30 June 2025 towards the end of September 2025.

 

 

 

 

 

Enquiries:

 

James Halstead plc

Tel: 0161 767 2500

Mark Halstead, Executive Chairman

Gordon Oliver, Chief Executive

David Drillingcourt, Finance Director

 

Hudson Sandler

Tel: 020 7796 4133

Nick Lyon / Nick Moore

Panmure Liberum (Nomad and Joint Broker)

Tel: 020 7886 2500

Ed Mansfield / Tom Scrivens

Zeus (Joint Broker)

Ben Thorne / Fraser Marshall

 

Tel: 020 3829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKFBQCBKDPOB
Date   Source Headline
8th May 20181:22 pmRNSForm 8.5 (EPT/NON-RI)
4th May 20185:09 pmRNSForm 8.5 (EPT/RI) - James Halstead PLC
4th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
4th May 201810:03 amRNSForm 8.3 - James Halstead
4th May 20188:52 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
3rd May 20181:47 pmRNSForm 8.5 (EPT/RI) - James Halstead PLC
3rd May 201812:04 pmRNSForm 8.3 - James Halstead
3rd May 201811:57 amRNSForm 8.3 - James Halstead
3rd May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
3rd May 20189:16 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
2nd May 20183:57 pmRNSStatement re Airea plc
2nd May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
2nd May 20189:00 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
1st May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
1st May 20189:51 amRNSForm 8.3 - James Halstead
1st May 20188:19 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
30th Apr 20184:31 pmRNSMavis Warren family - Form 8.3 - James Halstead
30th Apr 20184:26 pmRNSEdith Hayhurst - Form 8.3 - James Halstead plc
30th Apr 20184:21 pmRNSExors Audrey Halstead - Form 8.3 - James Halstead
30th Apr 201811:50 amRNSForm 8.5 (EPT/NON-RI)
30th Apr 20189:58 amRNSForm 8.5 (EPT/RI) - James Halstead
27th Apr 20181:53 pmRNSPanmure Gordon - Form 8.5 (EPT/RI) James Halstead
27th Apr 201811:50 amRNSForm 8.5 (EPT/NON-RI)
27th Apr 201810:43 amRNSForm 8.3 - James Halstead
26th Apr 201812:54 pmRNSForm 8.5 (EPT/NON-RI)
24th Apr 201811:43 amRNSForm 8.3 - James Halstead
24th Apr 201811:21 amRNSForm 8.3 - James Halstead
24th Apr 201810:13 amRNSForm 8.3 - James Halstead
23rd Apr 20183:45 pmRNSForm 8.3 - James Halstead
18th Apr 20185:50 pmRNSAmendment - Form 8 (OPD) JAMES HALSTEAD PLC
18th Apr 20183:50 pmRNSAmendment - Form 8 (OPD) JAMES HALSTEAD PLC
18th Apr 20183:12 pmRNSAmendment - Form 8 (OPD) JAMES HALSTEAD PLC
18th Apr 20181:50 pmRNSForm 8 (OPD) JAMES HALSTEAD PLC
18th Apr 201811:50 amRNSForm 8.5 (EPT/NON-RI)
18th Apr 201811:30 amRNSForm 8.3 - James Halstead plc
16th Apr 201811:50 amRNSForm 8.5 (EPT/NON-RI)
13th Apr 201811:58 amRNSForm 8.3 - James Halstead PLC
13th Apr 201811:50 amRNSForm 8.5 (EPT/NON-RI)
12th Apr 201811:50 amRNSForm 8.5 (EPT/NON-RI)
11th Apr 201811:50 amRNSForm 8.5 (EPT/NON-RI)
10th Apr 201811:50 amRNSForm 8.5 (EPT/NON-RI)
9th Apr 201811:50 amRNSForm 8.5 (EPT/NON-RI)
9th Apr 201810:50 amRNSForm 8.3 - James Halstead PLC
6th Apr 20182:36 pmRNSForm 8.3 - James Halstead plc
6th Apr 201812:47 pmRNSForm 8.5 (EPT/NON-RI)
5th Apr 20187:00 amRNSStmnt re Share Price Movement - Replacement
4th Apr 20185:22 pmRNSStmnt re Share Price Movement
27th Mar 20187:00 amRNSInterim Results
20th Mar 201811:29 amRNSNotice of Results
29th Jan 20187:00 amRNSPre Close Trading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.